CDTX vs. GNTA, AVRO, LENZ, IKNA, TSBX, ALGS, TARA, ENTX, ATRA, and INAB
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Genenta Science (GNTA), AVROBIO (AVRO), LENZ Therapeutics (LENZ), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Aligos Therapeutics (ALGS), Protara Therapeutics (TARA), Entera Bio (ENTX), Atara Biotherapeutics (ATRA), and IN8bio (INAB). These companies are all part of the "biological products, except diagnostic" industry.
Cidara Therapeutics (NASDAQ:CDTX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.
Genenta Science has lower revenue, but higher earnings than Cidara Therapeutics.
Cidara Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 7.4% of Cidara Therapeutics shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Cidara Therapeutics had 10 more articles in the media than Genenta Science. MarketBeat recorded 12 mentions for Cidara Therapeutics and 2 mentions for Genenta Science. Cidara Therapeutics' average media sentiment score of 0.23 beat Genenta Science's score of 0.14 indicating that Cidara Therapeutics is being referred to more favorably in the media.
Genenta Science has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -73.46%. Genenta Science's return on equity of 0.00% beat Cidara Therapeutics' return on equity.
Cidara Therapeutics presently has a consensus target price of $71.25, suggesting a potential upside of 535.59%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 664.53%. Given Genenta Science's higher probable upside, analysts plainly believe Genenta Science is more favorable than Cidara Therapeutics.
Cidara Therapeutics received 433 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 70.24% of users gave Cidara Therapeutics an outperform vote.
Summary
Cidara Therapeutics beats Genenta Science on 9 of the 16 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
